Clinical Trial Update: Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating Relmacabtagene Autoleucel as first-line therapy for high-risk large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• Relmacabtagene Autoleucel (relmacabtagene autoleucel)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: B-cell Lymphoma | Phase 2 | Status: UNKNOWN